During the past decade, Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 12 clinical trials were completed, i.e. on average, 70.6% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 7 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Pfizer" with 2 trials sponsored, "Allecra" with 1 trials sponsored, "Avalo Therapeutics, Inc." with 1 trials sponsored and "Biota Scientific Management Pty Ltd" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Department of Health and Human Services" with 1 trials as a collaborator and "Latin American Cooperative Oncology Group" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional" are "Breast Cancer" (4 trials), "Breast Neoplasms" (2 trials), "Non-Small Cell Lung Cancer" (2 trials), "Acute Cough" (1 trials) and "Alzheimer Disease" (1 trials). Many other conditions were trialed in "Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional" in a lesser frequency.

Most popular intervention types in "Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional" are "Drug" (22 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Atezolizumab" (5 trials), "Pertuzumab" (5 trials), "Trastuzumab" (5 trials) and "Capecitabine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional" are 20 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".